In the latest session on Tuesday, 22 September 2026, Moderna opened at USD 168.58. During the day, the shares reached a high ...

Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a ...

Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with ...

Sanofi (Nasdaq: SNY) deprioritized its mRNA flu shot effort. But it is still vigorously defending its substantial share of the flu vaccine market, with its egg-grown Fluzone products and egg-free ...

Moderna shares (MRNA) climbed 5.56% toto $182.56, with the stock hitting it's highest level in more than 3 years intraday at $187.20. Up 491.57% since the turn of calendar 2026, the shift in sentiment ...

Moderna’s former Cambridge headquarters could be turned into affordable housing. Alexandria Real Estate Equities is looking to unlock an additional 250,000 square feet of commercial development at ...

Moderna has surged over 500% this year while its closest messenger RNA rival sits nearly flat, and a single late-October data presentation at ESMO could either cement the rally or erase it overnight.

Merck and Moderna build a custom mRNA vaccine for each melanoma patient from tumor mutations. The strategy stumbles in cancers lacking enough targets ...

A century-old building that once served as Moderna's Cambridge headquarters could be reborn as affordable housing, under a ...

Findings showed the study did not meet its primary endpoint of preventing CMV infection in seronegative participants. Vaccine efficacy against CMV infection was reported to be between 6% to 23% ...

Moderna Inc. stocks have been trading up by 13.31 percent after breakthrough vaccine data spurred strong investor optimism. Key Takeaways MRNA Traders Need Now FDA cleared Moderna’s updated 2026–2027 ...